Pamplona

• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• Dose determination study of a mix of Dermatophagoides allergenic extracts (pteronyssinus and farinae) for immunotherapy treatment, administe … Recruiting
  2025-521522-15-00 4 2025-11-05 Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant … Recruiting
  2024-516794-70-00 4 2025-11-03 Metastatic non-squamous non-small cell lung cancer
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520613-31-00 5 2025-10-31 Agitation Associated with Alzheimer’s Disease
• TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting
  2024-519917-72-00 5 2025-10-29 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Clinical trial to assess the efficacy and safety of a post-coital intravaginal gel of PKB171 in couples with mild male factor infertility. Recruiting
  2023-503850-11-00 10 2025-10-28 Oligospermia and/or asthenozoospermia
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• OMTX705-006 Phase 1b Recruiting
  2025-521872-69-00 3 2025-10-28 Advanced/Metastatic Pancreatic Adenocarcinoma
• A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube … Recruiting
  2024-517184-23-00 4 2025-10-16 platinum-resistant advanced high-grade epithelial ovarian, primary per
• Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea … Recruiting
  2024-511459-16-00 9 2025-10-14 Histologically confirmed pancreatic adenocarcinoma with liver metastas
• A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre … Recruiting
  2024-512421-92-00 7 2025-10-14 Unresectable, Locally Advanced or Metastatic Cancer
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro … Recruiting
  2024-520156-22-00 4 2025-10-08 Metastatic hormone-sensitive prostate cancer
• VALIDATION OF THE SENTINEL LYMPH NODE TECHNIQUE IN EARLY-STAGE OVARIAN CANCER (SENTOV II) Recruiting
  2024-520189-67-00 5 2025-10-08 OVARIAN CANCER
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 Lung Cancer
• A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients … Recruiting
  2024-514152-32-00 3 2025-10-06 Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)
• A study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease Recruiting
  2025-521023-75-00 4 2025-10-03 Immune system diseases
• A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting
  2025-521975-30-00 4 2025-10-03 Newly Diagnosed Multiple Myeloma
• A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo … Recruiting
  2025-520499-24-00 5 2025-10-01 Moderate to Severe Platysma Prominence
• A study to learn about nadofaragene firadenovec given alone or together with gemcitabine and docetaxel or, pembrolizumab in adults with non- … Recruiting
  2024-512177-27-01 5 2025-09-29 High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invas
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight: … Recruiting
  2024-520210-21-00 5 2025-09-19 Crohn’s Disease
• Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting
  2025-520672-26-00 9 2025-09-16 Gastrointestinal Neoplasms
• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, a … Recruiting
  2024-514186-18-00 1 2025-09-09 Systemic Lupus Erythematosus

Showing 193–216 of 821 trials